Literature DB >> 11174479

Polymorphism of TP53 codon 72 and the risk of cervical cancer among Korean women.

J W Kim1, J W Roh, N H Park, Y S Song, S B Kang, H P Lee.   

Abstract

OBJECTIVE: It has recently been suggested that white women who are homozygous for the allele of the gene for wild-type p53 protein (TP53) that encodes arginine at position 72 are more susceptible to human papillomavirus-associated cervical carcinoma than are women who are heterozygous for this polymorphism and women who are homozygous for the allele that encodes proline at that position. This study was undertaken to analyze whether the TP53 codon 72 single-nucleotide polymorphism might be correlated with the risk of cervical cancer among Korean women. STUDY
DESIGN: Peripheral blood samples from patients with invasive cervical carcinoma yielding a positive result for human papillomavirus 16 (n = 100), patients with cervical intraepithelial neoplasia grade III (n = 134), and healthy control subjects (n = 100) were examined. The presence and genotype of human papillomavirus in cancerous cervical tissues were determined by E6, E7-based nested polymerase chain reaction. Germline genomic deoxyribonucleic acid was extracted from peripheral blood leukocytes and examined by polymerase chain reaction amplification of the specific allele assay as described by Storey et al. Deoxyribonucleic acid samples from patients whose TP53 sequences had been determined by direct sequencing were used as positive control preparations.
RESULTS: The respective proportions of individuals who are homozygous for the arginine allele, homozygous for the proline allele, and heterozygous for the 2 alleles were 40%, 12%, and 48% among women with invasive cervical carcinoma, 52%, 9%, and 39% among women with cervical intraepithelial neoplasia grade III, and 52%, 11%, and 37% among the control group. No significant differences in the frequency of codon 72 alleles were found among the 3 groups (chi(2) = 4.414; P =.353; degrees of freedom = 4).
CONCLUSION: This finding suggests that the risk of cervical cancer may not be increased for Korean women with the allele of TP53 encoding arginine at codon 72.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11174479     DOI: 10.1067/mob.2001.108329

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  6 in total

1.  The preliminary study of p53 codon 72 polymorphism and risk of cervical carcinoma in Gabonese women.

Authors:  Samira Zoa Assoumou; Anicet Luc M Boumba; Angelique Ndjoyi-Mbiguino; Abdelkrim Khattabi; Moulay Mustapha Ennaji
Journal:  Med Oncol       Date:  2014-12-12       Impact factor: 3.064

2.  A comprehensive review on host genetic susceptibility to human papillomavirus infection and progression to cervical cancer.

Authors:  Koushik Chattopadhyay
Journal:  Indian J Hum Genet       Date:  2011-09

3.  BRIP1 inhibits the tumorigenic properties of cervical cancer by regulating RhoA GTPase activity.

Authors:  Wei Zou; Xiangdong Ma; Wei Hua; Biliang Chen; Yanhong Huang; Detang Wang; Guoqing Cai
Journal:  Oncol Lett       Date:  2015-11-24       Impact factor: 2.967

4.  The ECCR1 rs11615, ERCC4 rs2276466, XPC rs2228000 and XPC rs2228001 polymorphisms increase the cervical cancer risk and aggressiveness in the Bangladeshi population.

Authors:  Shiba Das; Lutfur Naher; Tutun Das Aka; Md Abdul Aziz; Samia Shabnaz; Mohammad Shahriar; Mohammad Safiqul Islam
Journal:  Heliyon       Date:  2021-01-09

5.  Role of human papillomavirus and cell cycle-related variants in squamous cell carcinoma of the oropharynx.

Authors:  Guojun Li; Zhigang Huang; Xingming Chen; Qingyi Wei
Journal:  J Biomed Res       Date:  2010-09

6.  Association between the p53 arginine/arginine homozygous genotype at codon 72 and human papillomavirus E6/E7 mRNA expression.

Authors:  Ana Carolina Silva Chuery; Ismael Dale Cotrim Guerreiro da Silva; Julisa Chamorro Lascasas Ribalta; Neila Maria de Góis Speck
Journal:  Braz J Infect Dis       Date:  2017-03-25       Impact factor: 3.257

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.